SMMT
Summit Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+28/100
Last price
17.28
▲ 0.01 (0.06%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
17.30
Prev close
17.27
Day high
17.53
Day low
16.53
Volume
5.87M
Market cap
$13.81B
P/E (TTM)
—
52W range
12.07 – 29.23
Day trading desk
Gap from prior close
+0.17%
Prior close 17.27
VWAP
17.18
+0.60% from price
Relative volume
1.91×
Unusually busy
Session range
6.47%
16.53 – 17.60
Position in range
70%
Near session high
ATR (14D)
1.17
6.75% of price
Prior day high
17.62
PDH
Prior day low
16.44
PDL
Bid / ask spread
—
Quote not published
Session volume
10.85M
Avg 5.67M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.61%
+3.7%
1M
-1.68%
-2.8%
3M
+10.33%
+5.8%
6M
-9.94%
-28.1%
YTD
-1.03%
-15.3%
1Y
-19.23%
-35.6%
3Y
+825.67%
+743.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SMMT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
645.31M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 12, 26 | DUGGAN ROBERT WILLIAM Chief Executive Officer |
BUY | 3.81M | $49.99M | Direct |
| Jun 12, 26 | ZANGANEH MAHKAM Chief Executive Officer |
BUY | 3.81M | $49.99M | Indirect |
| Jun 4, 26 | DUGGAN ROBERT WILLIAM Chief Executive Officer |
BUY | 100.00K | $1.46M | Indirect |
| Jun 4, 26 | ZANGANEH MAHKAM Chief Executive Officer |
BUY | 100.00K | $1.46M | Indirect |
| Jun 4, 26 | SONI MANMEET SINGH Chief Operating Officer |
BUY | 50.00K | $722.25K | Direct |
| Oct 21, 25 | DUGGAN ROBERT WILLIAM Chief Executive Officer |
STOCK | 14.25M | $267.00M | |
| Oct 21, 25 | DUGGAN ROBERT WILLIAM Chief Executive Officer |
BUY | 26.68K | $499.98K | Indirect |
| Oct 21, 25 | ZANGANEH MAHKAM Chief Executive Officer |
STOCK | 14.25M | $267.00M | Indirect |
| Oct 21, 25 | ZANGANEH MAHKAM Chief Executive Officer |
BUY | 26.68K | $499.98K | Indirect |
| Oct 21, 25 | SONI MANMEET SINGH Chief Operating Officer |
STOCK | 53.36K | $999.99K | Direct |
| Oct 21, 25 | ANAND BHASKAR Officer |
STOCK | 26.68K | $499.98K | Direct |
| Oct 21, 25 | XIA YU Director |
BUY | 533.62K | $10.00M | Indirect |
| Sep 11, 25 | DUGGAN ROBERT WILLIAM Chief Executive Officer |
BUY | 338.39K | $5.98M | Direct |
| Sep 11, 25 | ZANGANEH MAHKAM Chief Executive Officer |
BUY | 338.39K | $5.98M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANAND BHASKAR |
Officer | 159.75K | Stock Award(Grant) |
DUGGAN ROBERT WILLIAM |
Chief Executive Officer | 610.02M | Purchase |
SONI MANMEET SINGH |
Chief Operating Officer | 3.12M | Purchase |
XIA YU |
Director | — | Purchase |
ZANGANEH MAHKAM |
Chief Executive Officer | — | Purchase |
Fundamentals
Market cap$13.81B
Enterprise value$13.14B
Revenue (TTM)—
Gross profit—
EBITDA$-874.67M
Net income$-856.09M
EPS (TTM)$-1.11
Free cash flow$-139.68M
Total cash$690.68M
Total debt$20.38M
Book value / share$0.79
Shares outstanding797.75M
Float152.28M
Short % of float26.26%
Dividend yield0.00%
Beta (5Y)-1.52
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.19
PEG ratio—
Price / sales—
Price / book21.80
EV / revenue—
EV / EBITDA-15.02
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-192.50%
Return on assets-101.61%
Debt / equity3.24
Current ratio6.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $705.00K | — | — |
| Operating revenue | $0 | $0 | $0 | $705.00K | — | — |
| Research & development | $537.67M | $150.78M | $59.47M | $52.00M | — | +256.6% |
| Selling, general & admin | $556.70M | $60.20M | $29.26M | $26.74M | — | +824.8% |
| Total operating expense | $1.09B | $210.98M | $88.73M | $64.33M | — | +418.7% |
| Operating income | -$1.09B | -$210.98M | -$88.73M | -$63.62M | — | -418.7% |
| Net interest income | $0 | -$8.69M | -$16.46M | -$2.89M | — | +100.0% |
| Pre-tax income | -$1.08B | -$221.30M | -$614.93M | -$78.78M | — | -387.8% |
| Tax provision | — | — | — | — | $0 | — |
| Net income | -$1.08B | -$221.31M | -$614.93M | -$78.78M | — | -387.8% |
| Net income to common | -$1.08B | -$221.31M | -$614.93M | -$78.78M | — | -387.8% |
| Basic EPS | -1.44 | -0.31 | -0.99 | -0.41 | — | -364.5% |
| Diluted EPS | -1.44 | -0.31 | -0.99 | -0.41 | — | -364.5% |
| EBIT | -$1.08B | -$212.62M | -$598.47M | -$74.38M | — | -407.7% |
| EBITDA | -$1.08B | -$212.53M | -$598.27M | -$73.12M | — | -407.9% |
| Basic shares | 747.70M | 718.54M | 619.65M | 193.34M | — | +4.1% |
| Diluted shares | 747.70M | 718.54M | 619.65M | 193.34M | — | +4.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.27M | $104.86M | $71.42M | $348.61M | — | +114.8% |
| Cash & short-term investments | $713.45M | $412.35M | $186.24M | $348.61M | — | +73.0% |
| Accounts receivable | — | — | $0 | $349.00K | $1.46M | — |
| Total current assets | $720.30M | $423.75M | $189.71M | $656.71M | — | +70.0% |
| Property, plant & equipment | $21.68M | $7.40M | $6.06M | $5.08M | — | +193.0% |
| Goodwill & intangibles | $2.00M | $1.86M | $1.89M | $1.80M | — | +7.3% |
| Total assets | $751.18M | $435.56M | $202.95M | $664.17M | — | +72.5% |
| Total current liabilities | $72.99M | $41.73M | $20.41M | $38.78M | — | +74.9% |
| Current debt | — | — | — | $19.77M | — | — |
| Long-term debt | — | — | $100.00M | $494.54M | — | — |
| Total debt | $20.89M | $7.22M | $106.10M | $518.76M | — | +189.4% |
| Total liabilities | $92.32M | $46.81M | $125.26M | $537.51M | — | +97.2% |
| Retained earnings | -$2.29B | -$1.21B | -$993.26M | -$378.33M | — | -88.9% |
| Shareholder equity | $658.86M | $388.75M | $77.69M | $126.65M | — | +69.5% |
| Working capital | $647.31M | $382.02M | $169.31M | $617.93M | — | +69.4% |
| Net tangible assets | $656.86M | $386.88M | $75.80M | $124.86M | — | +69.8% |
| Shares issued | 775.37M | 737.63M | 701.66M | 211.09M | — | +5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.08B | -$221.31M | -$614.93M | -$78.78M | -387.8% |
| Depreciation & amortisation | $146.00K | $89.00K | $198.00K | $1.26M | +64.0% |
| Stock-based compensation | $732.42M | $50.98M | $14.11M | $11.95M | +1,336.7% |
| Change in working capital | $31.42M | $15.48M | -$516.00K | $9.87M | +103.0% |
| Operating cash flow | -$322.93M | -$142.11M | -$76.76M | -$41.58M | -127.2% |
| Capital expenditure | -$657.00K | -$139.00K | -$128.00K | -$624.00K | -372.7% |
| Investing cash flow | -$174.31M | -$205.34M | -$587.77M | -$624.00K | +15.1% |
| Financing cash flow | $617.53M | $381.23M | $86.51M | $620.24M | +62.0% |
| Free cash flow | -$323.59M | -$142.25M | -$76.89M | -$42.21M | -127.5% |
| End cash position | $225.58M | $105.19M | $71.42M | $648.61M | +114.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $157.73M | $132.62M | $147.29M | $131.10M | $208.02M | — | +18.9% |
| Selling, general & admin | $62.76M | $62.59M | $77.58M | $103.11M | $360.42M | — | +0.3% |
| Total operating expense | $220.50M | $195.21M | $224.88M | $234.21M | $568.44M | — | +13.0% |
| Operating income | -$220.50M | -$195.21M | -$224.88M | -$234.21M | -$568.44M | — | -13.0% |
| Net interest income | — | — | $0 | $0 | $0 | $0 | — |
| Pre-tax income | -$215.70M | -$189.42M | -$219.12M | -$231.79M | -$565.71M | — | -13.9% |
| Net income | -$215.70M | -$189.42M | -$219.17M | -$231.79M | -$565.71M | — | -13.9% |
| Net income to common | -$215.70M | -$189.42M | -$219.17M | -$231.79M | -$565.71M | — | -13.9% |
| Basic EPS | -0.28 | -0.24 | -0.29 | -0.31 | -0.76 | — | -16.7% |
| Diluted EPS | -0.28 | -0.24 | -0.29 | -0.31 | -0.76 | — | -14.6% |
| EBIT | -$220.50M | -$195.21M | -$219.12M | -$231.79M | -$568.44M | — | -13.0% |
| EBITDA | -$220.45M | -$195.17M | -$219.08M | -$231.75M | -$568.40M | — | -13.0% |
| Basic shares | 778.18M | 775.46M | 766.40M | 743.42M | 742.62M | — | +0.4% |
| Diluted shares | 778.18M | 775.46M | 766.40M | 743.42M | 742.62M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $419.37M | $106.52M | $225.27M | $238.55M | $297.87M | +293.7% |
| Cash & short-term investments | $690.68M | $598.73M | $713.45M | $238.55M | $297.87M | +15.4% |
| Total current assets | $720.58M | $616.60M | $720.30M | $246.47M | $309.24M | +16.9% |
| Property, plant & equipment | $21.19M | $21.06M | $21.68M | $6.23M | $6.24M | +0.6% |
| Goodwill & intangibles | $1.97M | $1.97M | $2.00M | $2.00M | $2.04M | +0.2% |
| Total assets | $752.18M | $647.86M | $751.18M | $261.73M | $324.04M | +16.1% |
| Total current liabilities | $103.57M | $83.27M | $72.99M | $64.93M | $60.33M | +24.4% |
| Total debt | $20.38M | $20.04M | $20.89M | $5.43M | $5.55M | +1.7% |
| Total liabilities | $122.20M | $101.92M | $92.32M | $69.47M | $64.60M | +19.9% |
| Retained earnings | -$2.70B | -$2.48B | -$2.29B | -$2.07B | -$1.84B | -8.7% |
| Shareholder equity | $629.98M | $545.93M | $658.86M | $192.26M | $259.44M | +15.4% |
| Working capital | $617.01M | $533.33M | $647.31M | $181.54M | $248.91M | +15.7% |
| Net tangible assets | $628.01M | $543.97M | $656.86M | $190.26M | $257.40M | +15.5% |
| Shares issued | 793.12M | 776.02M | 775.37M | 744.44M | 742.81M | +2.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$215.70M | -$189.42M | -$219.17M | -$231.79M | -$565.71M | — | -13.9% |
| Depreciation & amortisation | $46.00K | $44.00K | $42.00K | $42.00K | $37.00K | — | +4.5% |
| Stock-based compensation | $68.71M | $72.79M | $111.78M | $130.76M | $478.78M | — | -5.6% |
| Change in working capital | $8.76M | -$1.68M | $8.34M | $7.86M | $21.41M | — | +623.2% |
| Operating cash flow | -$141.12M | -$122.29M | -$101.94M | -$93.08M | -$66.74M | — | -15.4% |
| Capital expenditure | -$909.00K | -$245.00K | -$164.00K | -$71.00K | — | -$422.00K | -271.0% |
| Investing cash flow | $222.90M | -$238.00K | -$485.16M | -$71.00K | $150.81M | — | +93,753.8% |
| Financing cash flow | $231.08M | $3.80M | $573.82M | $33.81M | $2.22M | — | +5,985.8% |
| Free cash flow | -$142.03M | -$122.54M | -$102.10M | -$93.15M | -$66.74M | — | -15.9% |
| End cash position | $419.68M | $106.83M | $225.58M | $238.88M | $298.19M | — | +292.8% |
Options analytics
Put / call volume
0.76
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-71.1% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
854
Contracts, this expiry
Put volume
648
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.21 | -0.21 | +2.0% |
| Mar 2026 | -0.21 | -0.18 | +14.2% |
| Dec 2025 | -0.01 | -0.21 | -1,386.3% |
| Sep 2025 | -0.04 | -0.23 | -429.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 12 | $54.14K | 0.0% |
| Next quarter | -0.25 | 11 | $2.99M | 0.0% |
| Current year | -0.85 | 11 | $2.94M | 0.0% |
| Next year | -0.86 | 10 | $41.88M | +1,327.0% |
Analyst targets & ownership
Mean target$29.82
High target$43.14
Low target$11.92
Implied upside72.56%
Analyst count13
ConsensusBUY
Strong buy / Buy1 / 10
Hold6
Sell / Strong sell0 / 0
Held by insiders80.89%
Held by institutions17.58%
Institutions holding329
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
16.52
+4.57% from price
SMA 20
17.00
+1.81% from price
SMA 50
15.18
+14.00% from price
SMA 100
15.13
+14.22% from price
SMA 200
16.36
+5.82% from price
EMA 12
16.78
+2.95% from price
EMA 26
16.38
+5.48% from price
EMA 50
15.87
+8.89% from price
RSI (14)
58.2
Neutral
MACD (12,26,9)
0.40
Hist -0.06
ATR (14)
1.17
6.74% of price
Realised vol 30D
68.1%
Annualised
Bollinger upper
18.40
20, 2σ
Bollinger lower
15.61
20, 2σ
50 / 200 cross
Death
15.18 vs 16.36
Trend bias
Above 200
+5.82%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.68
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
68.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-52.9%
Peak to trough
Max drawdown 5Y
-87.9%
Peak to trough
ATR 14
1.17
6.74% of price
Beta (reported)
-1.52
5Y monthly, from filing
Short interest
Shares short
41.08M
Prior 37.43M
Change vs prior
+9.7%
Shorts adding
% of float
26.26%
Heavily shorted
% of shares out
5.15%
Against total outstanding
Days to cover
6.4
Crowded exit
Float
152.28M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Sep 29, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Sep 23, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Sep 9, 26 | Jefferies | UPGRADE | Hold | Buy |
| Aug 26, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 25, 26 | Bernstein | UPGRADE | Underperform | Market Perform |
| Aug 18, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 12, 26 | Leerink Partners | UPGRADE | Underperform | Market Perform |
| Jul 24, 26 | Stifel | MAINTAINED | Buy | Buy |
| Jul 24, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 23, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| May 22, 26 | Bernstein | INITIATED | — | Underperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-26
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-22
Headlines
Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
BeInCrypto · 3h ago
AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos
Quartz · 17h ago
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Zacks · 2d ago
Summit Therapeutics Secures $2 Billion Investment From AstraZeneca
MT Newswires · 2d ago
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Business Wire · 2d ago
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
Simply Wall St. · 4d ago
Sector Update: Healthcare Stocks Steady Late Afternoon
MT Newswires · 4d ago
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
GuruFocus.com · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.